Detection of MAGE-4 Protein Sera of Patients with Liver Cirrhosis a useful maker for prediction of hepatocellular carcinoma

肝硬化患者血清MAGE-4蛋白检测对预测肝细胞癌有用

• 批准号: 10670522
• 负责人: TANAKA Masatoshi
• 金额: $ 1.98万
• 依托单位: Kurume University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1998
• 资助国家: 日本
• 起止时间: 1998 至 1999
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-10670522/
• 关键词: Tumor rejection antigen; MAGE-4; Hepatocellular carcinoma; Liver cirrhosis; Prediction of Cancer; 肝細胞癌

The majority of hepatocellular carcinomas (HCC) in Japan are caused from liver cirrhosis (LC) patients who have long suffered with hepatitis virus infection. Development of a useful serum marker for prediction of HCC is needed for better treatment and care of these patients. We previously reported that the MAGE-4 protein in sera of both HCC and LC patients were significantly higher than those of the control.This study has addressed whether level of MAGE-4 protein is useful for prediction of HCC by measurement of the serum MAGE-4 protein in LC (n=61) patients as a control at least 3 different times within 8 years. HCC was observed in 28 (46%) of these LC patients during this period, respectively. MAGE-4 protein was positive (>1.15 ng/ml) in 14 of 28 HCC patients (50%) before the diagnosis of LICC. And MAGE-4 protein was positive in only 3 of 33 LC patients (9%) who were not diagnosed as HCC. Levels of MAGE-4 protein in 7 or 5 patients were positive one or two year before the time of diagnosis of HCC, respectively. MAGE-4 protein decreased after the treatment of HCC in all the 6 patients tested, and became negative in 4 patients.We then performed the uni-valiated analysis of the predicting risk factors of HCC : gender, age, scrum AST, AFP value and MAGE-4 in 28 patients diagnosed as HCC. AFP level (over 20 ng/ml) (p=0.02) and MAGE-4 protein level (p=0.01) were significant as a factor for prediction of HCC.The multi-variated analysis was also performed. The MAGE-4 protein level in sera was the most significant risk factor for the prediction (p = 0.002).Thus, level of serum MAGE-4 was better that the any other serum markers tested for prediction of HCC in LC patients.Measurement of serum MAGE-4 could be a novel tool for prediction of HCC in LC patients.

日本的大部分肝细胞癌（HCC）是由长期感染肝炎病毒的肝硬化（LC）患者引起的。为了更好地治疗和护理这些患者，需要开发一种用于预测 HCC 的有用血清标志物。我们之前报道过 HCC 和 LC 患者血清中的 MAGE-4 蛋白显着高于对照组。本研究通过测量血清 MAGE-4 蛋白水平来探讨 MAGE-4 蛋白水平是否有助于预测 HCC。 4 蛋白在 LC (n=61) 患者中作为对照，在 8 年内至少 3 次不同的时间。在此期间，这些 LC 患者中分别有 28 名 (46%) 观察到 HCC。在诊断 LICC 之前，28 名 HCC 患者中有 14 名 (50%) 的 MAGE-4 蛋白呈阳性 (>1.15 ng/ml)。 33 名未诊断为 HCC 的 LC 患者中，只有 3 名（9%）MAGE-4 蛋白呈阳性。 7 名或 5 名患者的 MAGE-4 蛋白水平分别在诊断 HCC 前一年或两年呈阳性。所检测的 6 名患者均在 HCC 治疗后 MAGE-4 蛋白下降，其中 4 名患者转为阴性。然后我们对预测 HCC 的危险因素：性别、年龄、scrum AST、AFP 值和28 名诊断为 HCC 的患者中存在 MAGE-4。 AFP 水平（超过 20 ng/ml）（p=0.02）和 MAGE-4 蛋白水平（p=0.01）作为预测 HCC 的重要因素。还进行了多变量分析。血清中的 MAGE-4 蛋白水平是预测的最显着风险因素 (p = 0.002)。因此，血清 MAGE-4 水平优于用于预测 LC 患者 HCC 的任何其他血清标志物。血清 MAGE-4 可能成为预测 LC 患者 HCC 的新工具。

项目成果

Shigeru Yutani: "Detection of the MAGE-4 protein sera of livercirrhosis patients could be useful as a predictive tool of hepatocellularcar cinoma"Hepatology. 30・4. 518A (1999)

Shigeru Yutani：“检测肝硬化患者的 MAGE-4 蛋白血清可作为肝细胞癌的预测工具”Hepatology 30・4 (1999)。